Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240019 · ClinicalTrials.gov registry record · NA
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
A NA study of Diabetic Nephropathy, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00240019: Completed NA study of Diabetic Nephropathy, sponsored by Stanford University.
NCT00240019 is a NA study of Diabetic Nephropathy that has completed, run by Stanford University. The registered enrollment target is 30 participants, below the 11,428-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00240019, a NA study of Diabetic Nephropathy, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.
Conditions Studied
Interventions
- DRUG Addition of furosemide 20 mg oral bid to baseline regimen
Study Locations (2)
California
- Kaiser Permanente of Northern California, Santa Clara and San Jose - Santa Clara
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-04 |
| Phase | NA |
What the finished NCT00240019 record still lists
NCT00240019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 11,428-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Diabetic Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Addition of furosemide 20 mg oral bid to baseline regimen is the first listed.
NCT00240019 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00240019 about?
NCT00240019 is a clinical study titled "Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.". The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibit...
What is the current status of trial NCT00240019?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2003-12. Estimated completion is 2006-04.
What conditions does trial NCT00240019 study?
This clinical trial studies the following conditions: Diabetic Nephropathy.
What interventions are being tested in trial NCT00240019?
The interventions under investigation include: Addition of furosemide 20 mg oral bid to baseline regimen (DRUG).
Who is sponsoring clinical trial NCT00240019?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00240019 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00240019's enrollment target sits among peer trials
30 8th of 9 higher than 2 of 9 other Diabetic Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RECRUITING
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
COMPLETED · Phase 2
-
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
COMPLETED · Phase 2
-
Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia